Orexo: Zubsolv Rx Data week 49

According to latest Symphony Health Solutions Rx data, Zubsolv tablets showed a market share of 5.97% (6.03%), 4-week rolling average. The total number of Zubsolv tablets sold week 49 (48) reaching 337,072 (347,959). Zubsolv prescriptions (TRx) recorded a market share of 5.98% (6.07%), 4-week rolling average. Total number of prescriptions reaching 11,865 (12,413) during the week.

The overall market (buprenorphine/naloxone products) showed a y/y growth rate of 7.6% (7.3%) (4-week rolling average unit sales). TRx showed a y/y growth rate by 6.6% (6.3%) (4-week rolling average).

Författaren ägde vid analystillfället aktier i bolaget.

Fler bolagsanalyser

Här listas fler bolagsanalyser ifrån Redeyes analysavdelning.

Publicerad Rubrik Analystyp
2017-02-20 Update
2017-02-20 Update
2017-02-20 Analys
2017-02-20 Update
2017-02-17 Update
2017-02-17 Update
2017-02-17 Update
2017-02-16 Update
2017-02-16 Update
2017-02-16 Update
2017-02-13 Update
2017-02-13 Update
2017-02-13 Update
2017-02-10 Update
2017-02-10 Update
2017-02-10 Update
2017-02-03 Update
2017-02-03 Analys
2017-02-01 Update
2017-01-31 Update
2017-01-27 Update
2017-01-27 Update
2017-01-27 Update
2017-01-26 Analys
2017-01-20 Update